mAbxience and Abbott Sign Strategic Agreement to Broaden Access to a Pipeline of Biosimilars in Key Emerging MarketsMiguel Martínez-Cava2023-10-05T16:05:09+02:00September 20, 2023|Press releases|
A 3D-printed human skin dressing, a migraine predictor and a smart insulin pen: the three startups selected for support by Insud Pharmatheoms2023-10-05T16:05:14+02:00February 18, 2019|Press releases|
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals markettheoms2022-08-01T17:18:20+02:00August 1, 2022|News|
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxiencetheoms2022-04-19T22:57:54+02:00April 19, 2022|News|
Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxiencetheoms2022-05-25T23:46:17+02:00March 31, 2022|News|
